Relapsing-Remitting Multiple Sclerosis clinical trials at UCLA

1 research study open to eligible people

Showing trials for

  • Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

    open to eligible people ages 18-50

    This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab.

    Torrance, California and other locations

Our lead scientists for Relapsing-Remitting Multiple Sclerosis research studies include .

Last updated: